- Wei, Tzu-Tang;
- Chandy, Mark;
- Nishiga, Masataka;
- Zhang, Angela;
- Kumar, Kaavya Krishna;
- Thomas, Dilip;
- Manhas, Amit;
- Rhee, Siyeon;
- Justesen, Johanne Marie;
- Chen, Ian Y;
- Wo, Hung-Ta;
- Khanamiri, Saereh;
- Yang, Johnson Y;
- Seidl, Frederick J;
- Burns, Noah Z;
- Liu, Chun;
- Sayed, Nazish;
- Shie, Jiun-Jie;
- Yeh, Chih-Fan;
- Yang, Kai-Chien;
- Lau, Edward;
- Lynch, Kara L;
- Rivas, Manuel;
- Kobilka, Brian K;
- Wu, Joseph C
Epidemiological studies reveal that marijuana increases the risk of cardiovascular disease (CVD); however, little is known about the mechanism. Δ9-tetrahydrocannabinol (Δ9-THC), the psychoactive component of marijuana, binds to cannabinoid receptor 1 (CB1/CNR1) in the vasculature and is implicated in CVD. A UK Biobank analysis found that cannabis was an risk factor for CVD. We found that marijuana smoking activated inflammatory cytokines implicated in CVD. In silico virtual screening identified genistein, a soybean isoflavone, as a putative CB1 antagonist. Human-induced pluripotent stem cell-derived endothelial cells were used to model Δ9-THC-induced inflammation and oxidative stress via NF-κB signaling. Knockdown of the CB1 receptor with siRNA, CRISPR interference, and genistein attenuated the effects of Δ9-THC. In mice, genistein blocked Δ9-THC-induced endothelial dysfunction in wire myograph, reduced atherosclerotic plaque, and had minimal penetration of the central nervous system. Genistein is a CB1 antagonist that attenuates Δ9-THC-induced atherosclerosis.